By JBizNews Desk
May 11, 2026
Johnson & Johnson Chairman and Chief Executive Officer Joaquin Duato this week reiterated the company’s commitment to invest more than $55 billion in the United States over the next four years, tying artificial intelligence, domestic manufacturing, and advanced medical research together as central pillars of the company’s long-term growth strategy.
Duato emphasized the investment initiative in recent public remarks and company materials as Johnson & Johnson continues expanding manufacturing capacity, AI-driven drug development, and research infrastructure across its pharmaceutical and medical-technology businesses.
The $55 billion commitment — first outlined earlier this year — represents approximately a 25% increase over the company’s spending during the prior four-year period and reflects a broader industry race to localize supply chains, accelerate drug discovery through AI, and strengthen U.S.-based production capabilities following years of geopolitical and pandemic-related disruptions.
At the center of the strategy is a new $2 billion biologics manufacturing facility currently under construction in Wilson, North Carolina.
The 500,000-square-foot plant is designed to manufacture advanced medicines targeting cancer, autoimmune disorders, and neurological diseases — categories increasingly driving growth and profitability across the pharmaceutical industry.
Johnson & Johnson has also confirmed plans for three additional advanced manufacturing facilities in the United States, though locations have not yet been publicly disclosed.
The company’s financial scale provides substantial support for the initiative.
Johnson & Johnson reported approximately $88.8 billion in full-year 2024 revenue, according to its most recent annual filings, with sales rising 4.3% year over year.
Its Innovative Medicine division generated the majority of revenue, while MedTech continued benefiting from growing demand for robotic surgery systems, cardiovascular devices, and hospital technology infrastructure.
The spinout of Johnson & Johnson’s consumer-health division into Kenvue sharpened the company’s focus further toward higher-margin pharmaceutical, biotechnology, and medical-device operations.
Artificial intelligence now plays a central role in that strategy.
Johnson & Johnson executives said AI technologies are increasingly being integrated into drug discovery, clinical-trial design, patient recruitment, manufacturing operations, and data analysis — areas where efficiency gains can dramatically reduce the cost and timeline associated with bringing new therapies to market.
The company’s approach reflects a broader shift underway throughout the pharmaceutical sector as machine-learning systems become increasingly embedded in biomedical research and development workflows.
Johnson & Johnson said its R&D priorities remain focused on six major growth categories: oncology, immunology, neuroscience, cardiovascular disease, robotic surgery, and vision care.
The company spent more than $32 billion on research, development, acquisitions, and strategic partnerships during 2025, including transactions involving Intra-Cellular Therapies and Halda Therapeutics, alongside approximately 40 additional collaborations, licensing agreements, and partnership deals.
The broader U.S. innovation ecosystem continues supporting the company’s thesis.
The Food and Drug Administration’s Center for Drug Evaluation and Research approved 50 novel medicines during 2024, while industry trade group PhRMA estimates that biopharmaceutical companies collectively invest more than $100 billion annually into U.S.-based research and development.
Johnson & Johnson’s domestic manufacturing push also reflects lessons drawn from the COVID-era supply-chain disruptions that exposed vulnerabilities tied to extended international logistics networks.
Major pharmaceutical and medical-device companies increasingly view localized production capacity as strategically critical after pandemic shortages disrupted supplies of medicines, medical equipment, and industrial inputs worldwide.
The company noted in filings with the Securities and Exchange Commission that government pricing pressure, litigation risks, patent disputes, and regulatory changes continue creating uncertainty across the pharmaceutical sector.
That backdrop makes the scale of Johnson & Johnson’s long-term U.S. investment especially notable.
Earlier this year, Duato reached a voluntary agreement with the Trump administration under which Johnson & Johnson committed to aligning certain drug prices more closely with levels in other developed nations while expanding Medicaid access to select medicines.
In return, the administration expressed support for the company’s broader manufacturing and innovation initiatives.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives,” Duato said at the time.
For investors, the $55 billion initiative reinforces a broader strategic shift increasingly visible across the global health-care industry.
The companies expected to dominate the next generation of medicine are no longer viewed simply as pharmaceutical manufacturers.
They are increasingly becoming vertically integrated scientific and technology platforms combining artificial intelligence, manufacturing depth, data infrastructure, and advanced research ecosystems capable of accelerating the path from laboratory discovery to patient treatment.
Johnson & Johnson’s bet is that the future leaders in health care will be the companies controlling not only the science itself, but also the factories, computing infrastructure, and AI systems powering the next era of medical innovation.
And at $55 billion, the company continues making that bet overwhelmingly inside the United States.
— JBizNews Desk
© JBizNews.com. All rights reserved. This article is original reporting by JBizNews Desk. Unauthorized reproduction or redistribution is strictly prohibited.
